Petanceska S S, Gandy S
New York University at Nathan Kline Institute, Orangeburg 10962, USA.
J Neurochem. 1999 Dec;73(6):2316-20. doi: 10.1046/j.1471-4159.1999.0732316.x.
One of the hallmarks of Alzheimer's disease is the accumulation of senile plaques in brain, extracellular lesions comprised mostly of aggregates of the amyloid beta-peptide (Abeta). Abeta is proteolytically derived from the Alzheimer's amyloid precursor protein (APP). The generation of Abeta and nonamyloidogenic derivatives of APP involves utilization of alternative processing pathways and multiple subcellular compartments. To improve our understanding of the regulation of APP processing, we investigated the effects of wortmannin, a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, on APP processing. PI3-kinases form a multifaceted family of enzymes that represent converging points for multiple signal transduction pathways and also act as key regulators of vesicular trafficking. In N2a neuroblastoma cells expressing either wild-type APP or the "Swedish" familial Alzheimer's disease-associated mutant variant of APP, wortmannin treatment resulted in decreased release of both Abeta and soluble APPalpha. In parallel, full-length APP and both processed derivatives accumulated inside the cells. These effects were not present at nanomolar concentrations of wortmannin, but only at micromolar concentrations, implying the possible involvement of a recently described trans-Golgi network (TGN)-associated PI3-kinase that is resistant to nanomolar concentrations of the inhibitor, but sensitive to micromolar concentrations. All effects were reversible when the drug was removed from the cell culture medium. Given the suspected site of action of this novel PI3-kinase activity at the TGN, it is tempting to speculate that the unexpected increase in the levels of both intracellular soluble APPalpha and intracellular Abeta might be due to wortmannin-induced covesiculation of APP together with its respective secretase enzymes within the TGN, leading to the execution of alpha-, beta-, and gamma-secretase reactions.
阿尔茨海默病的一个标志性特征是大脑中出现老年斑,这些细胞外病变主要由β淀粉样肽(Aβ)聚集体构成。Aβ是由阿尔茨海默病淀粉样前体蛋白(APP)经蛋白水解产生的。APP生成Aβ及非淀粉样生成衍生物涉及到不同加工途径和多个亚细胞区室的利用。为了更好地理解APP加工的调控机制,我们研究了磷脂酰肌醇3激酶(PI3激酶)抑制剂渥曼青霉素对APP加工的影响。PI3激酶构成一个多方面的酶家族,它们是多个信号转导途径的汇聚点,也是囊泡运输的关键调节因子。在表达野生型APP或与“瑞典型”家族性阿尔茨海默病相关的APP突变体的N2a神经母细胞瘤细胞中,渥曼青霉素处理导致Aβ和可溶性APPα的释放均减少。与此同时,全长APP及其两种加工衍生物在细胞内积累。这些效应在纳摩尔浓度的渥曼青霉素下不存在,仅在微摩尔浓度时出现,这意味着可能涉及一种最近描述的与反式高尔基体网络(TGN)相关的PI3激酶,该激酶对纳摩尔浓度的抑制剂具有抗性,但对微摩尔浓度敏感。当药物从细胞培养基中去除时,所有效应都是可逆的。鉴于这种新型PI3激酶活性在TGN的推测作用位点,很容易推测细胞内可溶性APPα和细胞内Aβ水平意外增加可能是由于渥曼青霉素诱导APP与其各自的分泌酶在TGN内共同形成小泡,导致α-、β-和γ-分泌酶反应的发生。